Pharmaceutical cost comparison analysis of antimicrobial use for surgical prophylaxis on gastrectomy patients in a tertiary care hospital.
The present study investigated the clinical effects and therapeutic cost of cefazolin (CEZ) and ampicillin/sulbactam (SBT/ABPC) compared to analyze cost-effectiveness for surgical prophylaxis in gastric cancer patients. 157 inpatients who underwent surgery for gastric cancer were investigated. There was no difference between the two groups with regard to sex, age, incidence of complication, stage of cancer, operative time and blood loss, length of hospitalization, the appearance of systematic inflammatory responses syndrome and the prophylactic effect of infection. Meanwhile, decision analysis indicated that the anticipated therapeutic cost per patient in CEZ group was less than that of SBT/ABPC group (USD 142.72 and USD 187.17, respectively). In this case, CEZ use was more cost-effective, insofar as only drug cost was considered.
Ise
Yuya
Y
Department of Pharmaceutical Service, Nippon Medical School Hospital, Tokyo, Japan. yuyaise@nms.ac.jp
Hagiwara
Ken
K
Onda
Mitsuko
M
Kamei
Miwako
M
Katayama
Shirou
S
Nishizawa
Kenji
K
Hirano
Masaaki
M
Kiyama
Teruo
T
D000667:Ampicillin / Q000191:economics* / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000191:economics*; D001424:Bacterial Infections / Q000453:epidemiology / Q000517:prevention & control; D002437:Cefazolin / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D004359:Drug Therapy, Combination; D005743:Gastrectomy; D006801:Humans; D007564:Japan; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control; D013274:Stomach Neoplasms / Q000601:surgery*; D013407:Sulbactam / Q000191:economics* / Q000627:therapeutic use
D000667:Ampicillin; D002437:Cefazolin; D013407:Sulbactam